JP2018526375A - 組み合わせ療法 - Google Patents

組み合わせ療法 Download PDF

Info

Publication number
JP2018526375A
JP2018526375A JP2018511130A JP2018511130A JP2018526375A JP 2018526375 A JP2018526375 A JP 2018526375A JP 2018511130 A JP2018511130 A JP 2018511130A JP 2018511130 A JP2018511130 A JP 2018511130A JP 2018526375 A JP2018526375 A JP 2018526375A
Authority
JP
Japan
Prior art keywords
cancer
compound
formula
pharmaceutically acceptable
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018511130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018526375A5 (enExample
Inventor
カポニグロ，ジョルダーノ
ホーン−スピローン，トーマス
レハー，ジョセフ
ヒラワット，サミット
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2018526375A publication Critical patent/JP2018526375A/ja
Publication of JP2018526375A5 publication Critical patent/JP2018526375A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018511130A 2015-08-28 2016-08-24 組み合わせ療法 Pending JP2018526375A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562211014P 2015-08-28 2015-08-28
US62/211,014 2015-08-28
PCT/IB2016/055049 WO2017037578A2 (en) 2015-08-28 2016-08-24 Combination therapy

Publications (2)

Publication Number Publication Date
JP2018526375A true JP2018526375A (ja) 2018-09-13
JP2018526375A5 JP2018526375A5 (enExample) 2019-10-03

Family

ID=56896741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018511130A Pending JP2018526375A (ja) 2015-08-28 2016-08-24 組み合わせ療法

Country Status (5)

Country Link
US (1) US20180256557A1 (enExample)
EP (1) EP3380097A2 (enExample)
JP (1) JP2018526375A (enExample)
CN (1) CN107921026A (enExample)
WO (1) WO2017037578A2 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015524472A (ja) * 2012-08-07 2015-08-24 ノバルティス アーゲー Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬
JP2016510591A (ja) * 2013-02-25 2016-04-11 ジェネンテック， インコーポレイテッド 薬物耐性ａｋｔ変異体を検出し治療するための方法及び組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20130072507A1 (en) * 2010-05-21 2013-03-21 Glaxosmithkline Llc Combination

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015524472A (ja) * 2012-08-07 2015-08-24 ノバルティス アーゲー Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬
JP2016510591A (ja) * 2013-02-25 2016-04-11 ジェネンテック， インコーポレイテッド 薬物耐性ａｋｔ変異体を検出し治療するための方法及び組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GARRETT J T; ET AL: "COMBINATION OF ANTIBODY THAT INHIBITS LIGAND-INDEPENDENT HER3 DIMERIZATION AND A P110α 以下備考", CANCER RESEARCH, vol. Vol:73, Nr:19, JPN5018005515, 5 August 2013 (2013-08-05), US, pages 6013 - 6023, ISSN: 0004296884 *
SADHNA R VORA; ET AL: "CDK 4/6 INHIBITORS SENSITIZE PIK3CA MUTANT BREAST CANCER TO PI3K INHIBITORS; SUPPLEMENTARY 以下備考", CANCER CELL, vol. V26 N1, JPN5018005513, July 2014 (2014-07-01), pages 1 - 31, ISSN: 0004296883 *

Also Published As

Publication number Publication date
WO2017037578A2 (en) 2017-03-09
CN107921026A (zh) 2018-04-17
WO2017037578A3 (en) 2017-04-20
EP3380097A2 (en) 2018-10-03
US20180256557A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
EP3340990B1 (en) Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer
CN111225903B (zh) 谷氨酰胺酶抑制剂疗法
KR20180041677A (ko) Mdm2 억제제 및 그의 조합물
US20210186973A1 (en) Combination of ribociclib and dabrafenib for treating or preventing cancer
KR20150141971A (ko) 이브루티닙 병용 요법
US10328066B2 (en) Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
JP2016529285A (ja) 細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ
KR20160020502A (ko) 제약 조합물
JP2018528949A (ja) Ｐｉ３ｋ阻害剤およびｍｄｍ２阻害剤を使用する組み合わせ療法
US10328065B2 (en) Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
DK2897644T3 (en) Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor and an aromatase inhibitor
JP2018526375A (ja) 組み合わせ療法
US20190365741A1 (en) Combinations of the cdk4/6 inhibitor lee011 and the mek1/2 inhibitor trametinib, optionally further comprising the pi3k inhibitor byl719 to treat cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190822

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190822

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200707

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210302